Literature DB >> 23055568

Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism.

Olivia O'Connell1, Alexander Repik, Jacqueline D Reeves, Maria Paz Gonzalez-Perez, Briana Quitadamo, Elizabeth D Anton, Maria Duenas-Decamp, Paul Peters, Rongheng Lin, Susan Zolla-Pazner, Davide Corti, Aaron Wallace, Shixia Wang, Xiang-Peng Kong, Shan Lu, Paul R Clapham.   

Abstract

HIV-1 R5 viruses vary extensively in their capacity to infect macrophages. R5 viruses that confer efficient infection of macrophages are able to exploit low levels of CD4 for infection and predominate in brain tissue, where macrophages are a major target for infection. HIV-1 R5 founder viruses that are transmitted were reported to be non-macrophage-tropic. Here, we investigated the sensitivities of macrophage-tropic and non-macrophage-tropic R5 envelopes to neutralizing antibodies. We observed striking differences in the sensitivities of Env(+) pseudovirions to soluble CD4 (sCD4) and to neutralizing monoclonal antibodies (MAbs) that target the CD4 binding site. Macrophage-tropic R5 Envs were sensitive to sCD4, while non-macrophage-tropic Envs were significantly more resistant. In contrast, all Envs were sensitive to VRC01 regardless of tropism, while MAb b12 conferred an intermediate neutralization pattern where all the macrophage-tropic and about half of the non-macrophage-tropic Envs were sensitive. CD4, b12, and VRC01 share binding specificities on the outer domain of gp120. However, these antibodies differ in their ability to induce conformational changes on the trimeric envelope and in specificity for residues on the V1V2 loop stem and β20-21 junction that are targets for CD4 in recruiting the bridging sheet. These distinct specificities of CD4, b12, and VRC01 likely explain the observed differences in Env sensitivity to inhibition by these reagents and provide an insight into the envelope mechanisms that control macrophage tropism. We present a model where the efficiency of bridging-sheet recruitment by CD4 is a major determinant of HIV-1 R5 envelope sensitivity to soluble CD4 and macrophage tropism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23055568      PMCID: PMC3536387          DOI: 10.1128/JVI.01834-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  A semiparametric approach to analysing dose-response data.

Authors:  Q J Nottingham; J B Birch
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

2.  Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.

Authors:  P D Kwong; R Wyatt; S Majeed; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Structure       Date:  2000-12-15       Impact factor: 5.006

3.  The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia.

Authors:  Rebecca L Dunfee; Elaine R Thomas; Paul R Gorry; Jianbin Wang; Joann Taylor; Kevin Kunstman; Steven M Wolinsky; Dana Gabuzda
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

4.  Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages.

Authors:  K Mori; M Rosenzweig; R C Desrosiers
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses.

Authors:  N Bannert; D Schenten; S Craig; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity.

Authors:  P R Gorry; G Bristol; J A Zack; K Ritola; R Swanstrom; C J Birch; J E Bell; N Bannert; K Crawford; H Wang; D Schols; E De Clercq; K Kunstman; S M Wolinsky; D Gabuzda
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children.

Authors:  Daniel L Tuttle; Cynthia B Anders; M Janette Aquino-De Jesus; Paul P Poole; Susanna L Lamers; Daniel R Briggs; Steven M Pomeroy; Louis Alexander; Keith W C Peden; Warren A Andiman; John W Sleasman; Maureen M Goodenow
Journal:  AIDS Res Hum Retroviruses       Date:  2002-03-20       Impact factor: 2.205

9.  Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates.

Authors:  S Li; J Juarez; M Alali; D Dwyer; R Collman; A Cunningham; H M Naif
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

10.  Independent evolution of macrophage-tropism and increased charge between HIV-1 R5 envelopes present in brain and immune tissue.

Authors:  Maria Paz Gonzalez-Perez; Olivia O'Connell; Rongheng Lin; W Matthew Sullivan; Jeanne Bell; Peter Simmonds; Paul R Clapham
Journal:  Retrovirology       Date:  2012-03-15       Impact factor: 4.602

View more
  15 in total

1.  Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor.

Authors:  Nicole Espy; Beatriz Pacheco; Joseph Sodroski
Journal:  Virology       Date:  2017-05-15       Impact factor: 3.616

2.  Δ(9)-Tetrahydrocannabinol treatment during human monocyte differentiation reduces macrophage susceptibility to HIV-1 infection.

Authors:  Julie C Williams; Sofia Appelberg; Bruce A Goldberger; Thomas W Klein; John W Sleasman; Maureen M Goodenow
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-23       Impact factor: 4.147

3.  HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.

Authors:  Briana Quitadamo; Paul J Peters; Alexander Repik; Olivia O'Connell; Zhongming Mou; Matthew Koch; Mohan Somasundaran; Robin Brody; Katherine Luzuriaga; Aaron Wallace; Shixia Wang; Shan Lu; Sean McCauley; Jeremy Luban; Maria Duenas-Decamp; Maria Paz Gonzalez-Perez; Paul R Clapham
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

4.  Ultradeep single-molecule real-time sequencing of HIV envelope reveals complete compartmentalization of highly macrophage-tropic R5 proviral variants in brain and CXCR4-using variants in immune and peripheral tissues.

Authors:  Robin L Brese; Maria Paz Gonzalez-Perez; Matthew Koch; Olivia O'Connell; Katherine Luzuriaga; Mohan Somasundaran; Paul R Clapham; James Jarad Dollar; David J Nolan; Rebecca Rose; Susanna L Lamers
Journal:  J Neurovirol       Date:  2018-04-23       Impact factor: 2.643

5.  Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer.

Authors:  David F Boyd; Dylan Peterson; Beth S Haggarty; Andrea P O Jordan; Michael J Hogan; Leslie Goo; James A Hoxie; Julie Overbaugh
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

6.  Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5.

Authors:  Megan E Mefford; Kevin Kunstman; Steven M Wolinsky; Dana Gabuzda
Journal:  Virology       Date:  2015-03-20       Impact factor: 3.616

7.  Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.

Authors:  Katie M Kilgore; Megan K Murphy; Samantha L Burton; Katherine S Wetzel; S Abigail Smith; Peng Xiao; Sharmila Reddy; Nicholas Francella; Donald L Sodora; Guido Silvestri; Kelly S Cole; Francois Villinger; James E Robinson; Bali Pulendran; Eric Hunter; Ronald G Collman; Rama R Amara; Cynthia A Derdeyn
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

8.  Phenotypic Correlates of HIV-1 Macrophage Tropism.

Authors:  Kathryn T Arrildt; Celia C LaBranche; Sarah B Joseph; Elena N Dukhovlinova; William D Graham; Li-Hua Ping; Gretja Schnell; Christa B Sturdevant; Laura P Kincer; Macpherson Mallewa; Robert S Heyderman; Annelies Van Rie; Myron S Cohen; Serena Spudich; Richard W Price; David C Montefiori; Ronald Swanstrom
Journal:  J Virol       Date:  2015-09-02       Impact factor: 5.103

9.  Identification of Emerging Macrophage-Tropic HIV-1 R5 Variants in Brain Tissue of AIDS Patients without Severe Neurological Complications.

Authors:  Maria Paz Gonzalez-Perez; Paul J Peters; Olivia O'Connell; Nilsa Silva; Carole Harbison; Sheila Cummings Macri; Saravanan Kaliyaperumal; Katherine Luzuriaga; Paul R Clapham
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

10.  Infection of ectocervical tissue and universal targeting of T-cells mediated by primary non-macrophage-tropic and highly macrophage-tropic HIV-1 R5 envelopes.

Authors:  Paul J Peters; Maria Paz Gonzalez-Perez; Thomas Musich; Tiffany A Moore Simas; Rongheng Lin; Abraham N Morse; Robin J Shattock; Cynthia A Derdeyn; Paul R Clapham
Journal:  Retrovirology       Date:  2015-06-09       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.